Sociedad Argentina de Lípidos sobre diagnóstico y tratamiento de las dislipemias en adultos 2019. Córdoba: Sociedad Argentina de Lípidos, 2019. 10. Douville P, Martel AR, Talbot J, Desmeules S, Langlois S, Agharazii M. Impact of age on glomerular fltration estimates. Nephrol Dial Transplant 24(1):97-103, 2009. 11. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD- EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 55(4):622-627, 2010. 12. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 167(11):1122-1129, 2007. 13. McCullough PA, Verrill TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med 122(2):25-34, 2010. 14. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta- analysis of individual participant data. Lancet Diabetes Endocrinol 3(7):514-525, 2015. 15. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efcacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385(9976):1397-1405, 2015. 16. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 377(9784):2181-2192, 2011. 17. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovi V, Hegbrant J, et al. HMG CoA reductase inhibitors (statins) for people with
CONCLUSIÓN Los pacientes con ERC evaluados en este estudio presentaban riesgo cardiovascular considerable y debían recibir estatinas de acuerdo con la guía actual de la SAL. Sin embargo, el uso de estatinas observado fue deficiente. La implementación de un enfoque multidisciplinario podría mejorar el tratamiento de estos pacientes. BIBLIOGRAFÍA 1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296-1305, 2004. 2. Shrof GR, Carlson MD, Mathew RO. Coronary artery disease in chronic kidney disease: need for a heart-kidney team-based approach. Eur Cardiol 7(16):e48, 2021. 3. Theoflis P, Vordoni A, Koukoulaki M, Vlachopanos G, Kalaitzidis RG. Dyslipidemia in chronic kidney disease: contemporary concepts and future therapeutic perspectives. Am J Nephrol 52(9):693-701, 2021. 4. Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Adv Exp Med Biol. 956:307-325, 2007. 5. Takx RAP, MacNabb MH, Emami H, Abdelbaky A, Singh P, Lavender ZR, et al. Increased arterial inflammation in individuals with stage 3 chronic kidney disease. Eur J Nucl Med Mol Imaging 43:333-339, 2016. 6. Fakhry M, Sidhu MS, Bangalore S, Mathew RO. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease. Rev Cardiovasc Med 21(2):157-162, 2020. 7. Mok Y, Ballew SH, Matsushita K. Chronic kidney disease measures for cardiovascular risk prediction. Atherosclerosis 335:110-118, 2021. 8. Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord 18(1):29-40, 2017. 9. Elikir G, C neo C, Lorenzatti A, Aimone D, Berg G, Corral P, et al. Guía de práctica clínica de la
76
Powered by FlippingBook